Application Note: Fail-Early Approach To Compound Screening Using A Dual Nuclear Staining Assay
Source: Genetix Limited
Toxicity studies are an essential component of progressing
compounds through the drug discovery process. Molecules
must be screened for non-specific, adverse biological
properties such as cytotoxicity. As a significant number of
compounds fail during ADMETox due to their toxicity, it is of
paramount importance to have an effective early indication
of any compounds that exhibit cytotoxic effects.
access the Application Note!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more